Eni SpA vs Zimmer Biomet Holdings Inc — how do they compare? Eni SpA trades at $55.61 (market cap $78.80B), while Zimmer Biomet Holdings Inc trades at $97 (market cap $18.65B). The key difference: Eni SpA is far larger — about 4.2× Zimmer Biomet Holdings Inc's market cap, and Eni SpA pays the higher dividend (4.45%). Which is the better fit depends on your goals.
| E | ZBH | |
|---|---|---|
Market Cap | $78.80B | $18.65B |
Sector | Energy | Health |
52-Week High | $57.61 | $107.71 |
52-Week Low | $34.03 | $79.58 |
Enterprise Value | $104.11B | $25.72B |
Dividend Yield | 4.45% | 0.98% |
Signals from Pluang's Aura AI — not financial advice
Eni (E) trades at $53.61, down 1.22% on the day, with a bullish technical signal from moving averages and a neutral stance from oscillators. Recent Q2 2026 earnings missed estimates despite 21.5% revenue growth, while the company increased its share buyback program. Valuation ratios appear attractive with a P/E of 12.08 and P/S of 0.79. Cash flow from operations remains strong at $13.33 billion for 2025, supporting dividend payments and strategic investments.
The outlook for Eni is cautiously optimistic, driven by production growth and strategic partnerships, but faces risks from commodity price volatility and geopolitical factors. Analyst consensus is mixed with 34.62% buy ratings, highlighting potential upside if operational execution improves and energy markets stabilize.
No Aura AI signal available yet.
Trailing returns across standard periods
Eni is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, the company produced 0.8 million barrels of liquids and 4.6 billion cubic feet of natural gas per day. At end-2021, Eni held reserves of 6.6 billion barrels of oil equivalent, 49% of which are liquids. The Italian government owns a 30.1% stake in the company. Eni is placing its renewable and low-carbon business in a separate entity, Plentitude
Read more on E →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →